Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma
ConclusionsThe association of variants of FASL and ABCC5 with survival outcome after chemotherapy was validated in patients with osteosarcoma. Our findings may provide a new insight into a more personalized treatment for patients with osteosarcoma.
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
More News: Bone Cancers | Cancer & Oncology | Chemotherapy | Genetics | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Osteosarcoma | Study